These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36966651)

  • 1. Synthesis and biological evaluation of theranostic Trastuzumab-SN38 conjugate for Near-IR fluorescence imaging and targeted therapy of HER2+ breast cancer.
    Kobzev D; Prasad C; Walunj D; Gotman H; Semenova O; Bazylevich A; Patsenker L; Gellerman G
    Eur J Med Chem; 2023 Apr; 252():115298. PubMed ID: 36966651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker.
    Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R
    J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
    Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates.
    Yao Y; Yu L; Su X; Wang Y; Li W; Wu Y; Cheng X; Zhang H; Wei X; Chen H; Zhang R; Gou L; Chen X; Xie Y; Zhang B; Zhang Y; Yang J; Wei Y
    J Control Release; 2015 Dec; 220(Pt A):5-17. PubMed ID: 26439663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
    Duro-Sánchez S; Nadal-Serrano M; Lalinde-Gutiérrez M; Arenas EJ; Bernadó Morales C; Morancho B; Escorihuela M; Pérez-Ramos S; Escrivá-de-Romaní S; Gandullo-Sánchez L; Pandiella A; Esteve-Codina A; Rodilla V; Dijcks FA; Dokter WHA; Cortés J; Saura C; Arribas J
    Cancer Res; 2022 Dec; 82(24):4670-4679. PubMed ID: 36222720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
    Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies.
    Valsasina B; Orsini P; Caruso M; Albanese C; Ciavolella A; Cucchi U; Fraietta I; Melillo N; Fiorentini F; Rizzi S; Salsa M; Isacchi A; Gasparri F
    Mol Cancer Ther; 2023 Dec; 22(12):1465-1478. PubMed ID: 37722716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
    Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.
    Loganzo F; Tan X; Sung M; Jin G; Myers JS; Melamud E; Wang F; Diesl V; Follettie MT; Musto S; Lam MH; Hu W; Charati MB; Khandke K; Kim KS; Cinque M; Lucas J; Graziani E; Maderna A; O'Donnell CJ; Arndt KT; Gerber HP
    Mol Cancer Ther; 2015 Apr; 14(4):952-63. PubMed ID: 25646013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology].
    Liang XJ; Gong LY; Zhou F; Zhou DM; Zhu JJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 51(5):797-804. PubMed ID: 31624380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers.
    Shin SH; Park YH; Park SS; Ju EJ; Park J; Ko EJ; Bae DJ; Kim SY; Chung CW; Song HY; Jang SJ; Jeong SY; Song SY; Choi EK
    Adv Sci (Weinh); 2021 Dec; 8(23):e2102414. PubMed ID: 34664433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding
    Avilés P; Domínguez JM; Guillén MJ; Muñoz-Alonso MJ; Mateo C; Rodriguez-Acebes R; Molina-Guijarro JM; Francesch A; Martínez-Leal JF; Munt S; Galmarini CM; Cuevas C
    Mol Cancer Ther; 2018 Apr; 17(4):786-794. PubMed ID: 29440297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
    von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
    Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
    Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
    Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
    Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate.
    Xiao D; Zhao L; Xie F; Fan S; Liu L; Li W; Cao R; Li S; Zhong W; Zhou X
    Theranostics; 2021; 11(6):2550-2563. PubMed ID: 33456559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.